Avalo Therapeutics to Attend Upcoming Investor Conferences in 2025

WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company specializing in therapies for immune dysregulation, has announced its participation in two prominent investor conferences in the near future. The management team will engage in a fireside chat at the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025, at 11:00 am ET, and will be available for one-on-one meetings during the BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.

The announcement reflects Avalo's commitment to transparency and its proactive approach in sharing insights about its clinical advancements. According to Christopher Sullivan, Chief Financial Officer at Avalo Therapeutics, “Participating in these esteemed conferences allows us to connect with investors and share our strategic vision for addressing unmet medical needs in the realm of immune dysregulation.” The investor conferences will feature live webcasts, with archived sessions available for replay for at least 30 days following the events.

Avalo Therapeutics focuses on developing innovative treatments for inflammatory diseases, with its lead asset, AVTX-009, being a humanized monoclonal antibody targeting interleukin-1β (IL-1β). This cytokine is a significant contributor to inflammation and is implicated in a range of autoimmune and inflammatory conditions. Dr. John Adams, an immunology expert at the University of Pennsylvania, highlights that “IL-1β is a validated target for therapeutic intervention, and inhibiting its activity has shown promise across various clinical settings, including dermatology and rheumatology.”

The implications of Avalo's research are substantial, as the company aims to address conditions like hidradenitis suppurativa, which currently lacks effective treatment options. This focus on immune dysregulation positions Avalo as a key player in the biopharmaceutical landscape, especially as the demand for innovative therapies continues to rise.

The significance of these conferences extends beyond investor engagement; they serve as a platform for Avalo to discuss its ongoing clinical trials and future research directions. The company’s commitment to advancing therapeutic options for patients underscores the growing recognition of immune dysregulation as a critical area of study in modern medicine.

As Avalo Therapeutics prepares for these investor conferences, the biotech community watches closely. The outcomes of such engagements may influence investor confidence and shape the future trajectory of the company’s clinical programs. With the increasing focus on innovative therapeutics in the biopharmaceutical sector, Avalo's progress in treating immune dysregulation positions it as a noteworthy entity to monitor in the coming years.

For more information about Avalo Therapeutics and its pipeline, interested parties can visit their official website at www.avalotx.com. For media inquiries, contact Christopher Sullivan at 410-803-6793 or via email at ir@avalotx.com.